在胃肠道疾病中治疗慢性内脏疼痛的新型治疗点
Fleur Veldman1, Christopher J Black2,3, Andrea Shin4
1Department of Gastroenterology-Hepatology, NUTRIM Research institute of Nutrition and Translational Research in Metabolism, Maastricht University Medical Center, Maastricht, The Netherlands.
British journal of pharmacology
|January 9, 2026
概括
慢性内脏疼痛的管理是具有挑战性的,因为对其原因的理解不足. 新型疗法,包括神经调节剂和神经刺激,显示出多模式治疗方法的前景.
科学领域:
- 胃肠病学 胃肠病学
- 疼痛医学 医学 疼痛医学
- 神经科学是一个神经科学.
背景情况:
- 慢性内脏疼痛显著影响生活质量.
- 病理生理学是复杂的,涉及到外围和中央机制.
- 像阿片类药物这样的当前治疗方法也有局限性.
研究的目的:
- 审查慢性内脏疼痛的新兴治疗策略.
- 突出了基于机制的多模式治疗的需要.
主要方法:
- 关于内脏疼痛病理生理学的当前文献的综述.
- 探索药理学 (神经调节剂,受体向治疗) 和非药理学 (神经刺激,心理治疗) 的方法.
主要成果:
- 神经调节剂对中央敏感性有好处.
- 针对受体的向疗法正在开发中.
- 目前正在探索非药理学策略.
结论:
- 有效的管理需要一个多式联运,基于机制的范式.
- 对于新的治疗方法,需要进一步的研究.
相关概念视频
Analgesia and Pain Management
1.5K
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
1.5K
Inflammatory Bowel Disease IV: Pharmacological Management
471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
471
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
564
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
564
Chronic Bowel Disorders: Introduction
743
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
743
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
607
Diarrhea, a condition marked by frequent loose or watery bowel movements, can be triggered by multiple factors such as viral or bacterial infections, food intolerances, anxiety, medications, and digestive disorders. Symptoms may include abdominal pain, bloating, nausea, and cramping. Severe or prolonged diarrhea can lead to complications like electrolyte imbalances, malnutrition, and dehydration if left untreated.
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
607
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.1K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.1K


